CLL
News
‘Promising’ new txs for most common adult leukemia
The FDA has already approved these treatments for some other blood cancers, but chronic lymphocytic leukemia (CLL) poses unique challenges.
News
CLL combo treatment: Phase-3 study inconclusive
Results of the clinical trial of a CLL drug triplet therapy, presented at ASCO 2023, showed that more data are needed to determine its long-term...
Conference Coverage
CLL: Venetoclax-obinutuzumab combo effective long term
Progression-free survival benefit of 1 year with venetoclax-obinutuzumab is sustained long term in chronic lymphocytic leukemia, trial analysis...
News
Ibrutinib + venetoclax: High-risk features don’t lessen CLL response
Expert cautions that upfront targeted therapies for CLL should be considered experimental, given the adverse events and lack of long-term follow-...
Conference Coverage
`Remarkable’: CAR T therapy for CLL/SLL
Primary analysis of the TRANSCEND CLL 004 trial showed that a single dose of CAR T therapy achieved durable responses in CLL and SLL, with a...
News
New CLL meds: Improved survival rates, 1990-2018
A just-published retrospective study shows nearly 30 years of steady progress in lengthening the lives of U.S. adults with CLL and other leukemias...
News
Venetoclax boosts ibrutinib in high-risk CLL
Most patients in a small study reached undetectable measurable disease after taking combo therapy for high-risk CLL.
News
CLL: Venetoclax combos top first-line chemoimmunotherapy
A triple-therapy combination yielded the best outcomes, but it should still be considered investigational.
News
CLL: Black patients die sooner than White patients
Researchers suspect that multiple factors – including biology – could be behind the racial disparity found in this large study.
Conference Coverage
Frontline CLL treatment: Avoiding adverse events
Single-agent frontline therapy helps patients with CLL live longer, but those at high risk of relapse may benefit from multiagent treatment.